SYK
Stryker Corporation
SYK's fundamentals are strong and it looks cheap: trading at 33x earnings, below its usual 43x. Analysts expect earnings growth.
SYK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
SYK's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
SYK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $312 | — |
| Current | 33x | $312 | — |
| Cheap | 37x | $344 | +10% |
| Fair | 43x | $402 | +29% |
| Expensive | 51x | $480 | +54% |
Historical ranges are pointers, not guarantees.
SYK's PE is in its cheap range at 33x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
SYK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for SYK, with profitability holding steady.
SYK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.99 | +70% |
| Q3 2026 | $9.39 | +23% |
| Q2 2026 | $9.65 | +28% |
| Q1 2026 | $8.64 | +17% |
| Q4 2025 | $8.40 | +8.2% |
| Q3 2025 | $7.61 | -18% |
| Q2 2025 | $7.55 | -16% |
| Q1 2025 | $7.40 | -16% |
| Q4 2024 | $7.76 | -5.9% |
SYK earned $9.39 per share over the past year, up 23% from the year before.
SYK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.5B | +7.6% |
| Q2 2026 | $6.6B | +9.4% |
| Q1 2026 | $6B | +2.6% |
| Q4 2025 | $7.2B | +11% |
| Q3 2025 | $6.1B | +10% |
| Q2 2025 | $6B | +11% |
| Q1 2025 | $5.9B | +12% |
| Q4 2024 | $6.4B | +11% |
SYK's revenue has grown year over year every quarter since late 2020: $6.5B last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -2.9 points |
| Q2 2026 | 25% | +6.7 points |
| Q1 2026 | 16% | +1.3 points |
| Q4 2025 | 25% | +16 points |
| Q3 2025 | 19% | -1 points |
| Q2 2025 | 18% | -0.9 points |
| Q1 2025 | 14% | -4.3 points |
| Q4 2024 | 9% | -13 points |
SYK's operating margin was 16% last quarter, down 2.9 points from the same quarter a year ago.
SYK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -9.5% |
| Q2 2026 | $1.1B | +14% |
| Q1 2026 | $415M | +227% |
| Q4 2025 | $1.9B | +13% |
| Q3 2025 | $1.4B | +3.8% |
| Q2 2025 | $928M | +93% |
| Q1 2025 | $127M | +243% |
| Q4 2024 | $1.7B | +20% |
SYK's free cash flow has been positive every quarter for seven years: $4.6B over the past year, up 12% from the year before.
SYK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.3M shares |
| 1 year | -0.5% | -2M shares |
| 3 years | +0.2% | +700K shares |
| 5 years | +0.5% | +2M shares |
| Available history | +1.3% | +4.8M shares |
SYK has 385M diluted shares, down 0.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
SYK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.9x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 2.1x | Moderate |
SYK's net debt is about 1.6 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
SYK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 51.7 | Neutral |
SYK's weekly RSI is 50 (neutral) and its Stochastic is 52 (neutral).
SYK PE vs Healthcare Sector
| Metric | SYK | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 9 | 29 | 20 pts below |
SYK is trading at 33x earnings, a 29% premium to the Healthcare sector's median of 26x.
SYK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $294.6 | 6% above |
| 20 week MA | $309.1 | 1.1% above |
| 50 week MA | $327.6 | 4.6% below |
| 100 week MA | $352.1 | 11% below |
| 200 week MA | $333.6 | 6.4% below |
SYK has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 6.4% below its 200-week average.
SYK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $210.6 | $237.1 | +13% |
| 2021 | $237.1 | $268.3 | +13% |
| 2022 | $268.3 | $242.8 | -9.5% |
| 2023 | $242.8 | $299.5 | +23% |
| 2024 | $299.5 | $367.1 | +23% |
| 2025 | $367.1 | $354.2 | -3.5% |
| 2026 YTD | $354.2 | $312.4 | -12% |
SYK has finished higher in four of the last six years. It's down 12% so far in 2026.